BioSpace News Archive

The Exclusive Research Report on “Advanced Parenteral Drug Delivery Devices Market with Industry-Primary Research, Secondary Research, Product Research, Revenue, Emerging Trends and Top Growing Companies 2020-2029”.

The Exclusive Research Report on “Allergy Diagnostics Market with Industry-Primary Research, Secondary Research, Product Research, Revenue, Emerging Trends and Top Growing Companies 2020-2029”.

New York State Attorney General Supports Company’s Proposed Global Opioid Settlement; Joining 47 Other State and U.S. Territory Attorneys General

Teleflex Incorporated (NYSE: TFX) today announced that 175,000 patients have now been treated globally* with its minimally invasive UroLift® System—a safe and effective treatment for Benign Prostatic Hyperplasia (BPH) that provides rapid symptom relief and improved quality of life, while preserving sexual function

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announced full-year results for 2019

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that it has entered into a mezzanine loan and security agreement with Silicon Valley Bank (“SVB”) and WestRiver Innovation Lending Fund VIII, L.P., pursuant to which the lenders have agreed to lend the Company up to $50.0 million in a series of term loans.

Bio-Path Holdings, Inc. announced that the Audit Committee of the Company’s Board of Directors approved the appointment of Ernst & Young LLP as the Company’s new independent registered public accounting firm, replacing former auditor, BDO USA, LLP.

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received the final minutes from a meeting with the U.S. Food and Drug Administration (FDA) held on February 5, 2020.

Nasdaq and AIM listed Tiziana Life Sciences plc (Nasdaq: TLSA) (AIM: TILS) has today announced that its TZLS-501 treatment could be a potential treatment for patients infected with coronavirus (COVID-19) who are at risk of respiratory failure.

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and twelve months ended December 31, 2019 on Wednesday, March 18, 2020.